<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>fruquintinib &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/fruquintinib/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sat, 17 Oct 2026 12:14:49 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.3</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>fruquintinib &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Fruquintinib May Edge Ahead in KRAS-Mutant Colorectal Cancer, But No Clear Winner Yet</title>
		<link>https://bioengineer.org/fruquintinib-may-edge-ahead-in-kras-mutant-colorectal-cancer-but-no-clear-winner-yet/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Sat, 17 Oct 2026 12:14:49 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Bayesian analysis]]></category>
		<category><![CDATA[bevacizumab]]></category>
		<category><![CDATA[fruquintinib]]></category>
		<category><![CDATA[KRAS mutation]]></category>
		<category><![CDATA[metastatic colorectal cancer]]></category>
		<category><![CDATA[Network Meta-Analysis]]></category>
		<category><![CDATA[overall survival]]></category>
		<category><![CDATA[precision oncology]]></category>
		<category><![CDATA[progression-free survival]]></category>
		<category><![CDATA[regorafenib]]></category>
		<category><![CDATA[TAS-102]]></category>
		<category><![CDATA[third-line therapy]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=426867</guid>

					<description><![CDATA[A Bayesian network meta-analysis of ten randomized trials finds that fruquintinib, regorafenib, and TAS-102 all extend survival in refractory metastatic colorectal cancer, with fruquintinib ranking first in KRAS-mutant patients but without proof of superiority.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">426867</post-id>	</item>
	</channel>
</rss>
